Form 4: Gilead Sciences CEO Daniel O'Day Reports Routine Stock Transactions Following RSU Vesting

Gilead Sciences, Inc. CEO and Chairman Daniel P. O'Day reported the acquisition of common stock through restricted stock unit conversion and a subsequent disposition for tax withholding purposes.

Summary

• On June 10, 2025, Daniel P. O'Day, Chairman and CEO of Gilead Sciences, Inc. (GILD), acquired 10,425 shares of common stock through the conversion of restricted stock units (RSUs).
• Following this acquisition, Mr. O'Day directly beneficially owned 630,693 shares of common stock.
• Concurrently, Mr. O'Day disposed of 4,968 shares of common stock at a price of $110.09 per share to satisfy tax withholding obligations related to the RSU vesting.
• After these transactions, Mr. O'Day's direct beneficial ownership of common stock adjusted to 625,725 shares.
• Additionally, Mr. O'Day holds 108,923 restricted stock units, each representing the contingent right to receive one share of Gilead Sciences' common stock, subject to a four-year vesting schedule (25% on the first anniversary of grant, then 6.25% quarterly).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The transactions represent a routine executive compensation event involving the vesting of restricted stock units and a subsequent sale to cover tax obligations. While shares were disposed of, the underlying acquisition through RSU conversion indicates continued executive alignment with shareholder interests.

Positives

• The acquisition of 10,425 shares of common stock through RSU conversion increases the CEO's direct ownership in the company, aligning his interests with shareholders.
• The transaction is a result of a pre-defined vesting schedule for executive compensation, indicating the company is adhering to its compensation plans.

Negatives

• The disposition of 4,968 shares, while for tax purposes, reduces the total number of shares directly held by the CEO immediately following the RSU conversion.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's financial performance or strategic direction, beyond the general vesting schedule for restricted stock units.

Industry Context

This Form 4 filing details a routine insider stock transaction related to executive compensation, which is common across all industries, including the biotechnology and pharmaceutical sector where Gilead Sciences operates. It does not provide specific insights into broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: The transactions reflect a routine aspect of executive compensation and do not indicate a significant change in the company's operational or financial outlook. The CEO's continued direct ownership aligns his interests with shareholders.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

Keywords

Gilead Sciences, GILD, Daniel O'Day, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Common Stock, Executive Compensation, Stock Vesting